WallStSmart

CryoCell International Inc (CCEL)vsJohnson & Johnson (JNJ)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 319032% more annual revenue ($99.33B vs $31.13M). JNJ leads profitability with a 16.2% profit margin vs -6.3%. CCEL appears more attractively valued with a PEG of 1.34. JNJ earns a higher WallStSmart Score of 54/100 (C-).

CCEL

Hold

47

out of 100

Grade: D+

Growth: 6.0Profit: 5.0Value: 7.0Quality: 5.5
Piotroski: 6/9Altman Z: -0.53

JNJ

Buy

54

out of 100

Grade: C-

Growth: 4.7Profit: 8.5Value: 2.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCELUndervalued (+33.5%)

Margin of Safety

+33.5%

Fair Value

$5.02

Current Price

$4.15

$0.87 discount

UndervaluedFair: $5.02Overvalued
JNJSignificantly Overvalued (-84.0%)

Margin of Safety

-84.0%

Fair Value

$145.14

Current Price

$270.47

$125.33 premium

UndervaluedFair: $145.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCEL3 strengths · Avg: 10.0/10
Return on EquityProfitability
129.2%10/10

Every $100 of equity generates 129 in profit

EPS GrowthGrowth
75.1%10/10

Earnings expanding 75.1% YoY

Debt/EquityHealth
-0.0410/10

Conservative balance sheet, low leverage

JNJ3 strengths · Avg: 8.7/10
Market CapQuality
$682.52B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
26.6%8/10

Strong operational efficiency at 26.6%

Free Cash FlowQuality
$6.36B8/10

Generating 6.4B in free cash flow

Areas to Watch

CCEL4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

Market CapQuality
$39.10M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.6%3/10

Operating margin of 0.6%

Altman Z-ScoreHealth
-0.532/10

Distress zone — elevated risk

JNJ4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
43.0x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-95.9%2/10

Earnings declined 95.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : CCEL

The strongest argument for CCEL centers on Return on Equity, EPS Growth, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.

Bear Case : CCEL

The primary concerns for CCEL are Revenue Growth, Market Cap, Operating Margin.

Bear Case : JNJ

The primary concerns for JNJ are Piotroski F-Score, PEG Ratio, P/E Ratio. A P/E of 43.0x leaves little room for execution misses.

Key Dynamics to Monitor

CCEL profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.

CCEL carries more volatility with a beta of 0.55 — expect wider price swings.

JNJ is growing revenue faster at 5.9% — sustainability is the question.

JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (54/100 vs 47/100), backed by strong 16.2% margins. CCEL offers better value entry with a 33.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CryoCell International Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Want to dig deeper into these stocks?